The FDA has decided to re-evaluate the ProSense System as a minimally invasive treatment option for patients with early-stage, low-risk breast cancer.
January 2024 Brief
Early data of afamitresgene autoleucel suggest substantial benefits for those with advanced synovial sarcoma who haven't responded to other treatments.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
